PGEN Insider Trading

Insider Ownership Percentage: 44.90%
Insider Buying (Last 12 Months): $49,999.55
Insider Selling (Last 12 Months): $0.00

Precigen Insider Trading History Chart

This chart shows the insider buying and selling history at Precigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Precigen Share Price & Price History

Current Price: $1.61
Price Change: Price Decrease of -0.1 (-5.85%)
As of 03/26/2025 05:00 PM ET

This chart shows the closing price history over time for PGEN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.71Closing price on 03/25/25:

SEC Filings (Institutional Ownership Changes) for Precigen (NASDAQ:PGEN)

33.51% of Precigen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PGEN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$4.54Mbought$2.68MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
Precigen logo
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Read More on Precigen

Today's Range

Now: $1.61
Low: $1.58
High: $1.71

50 Day Range

MA: $1.64
Low: $1.11
High: $2.03

52 Week Range

Now: $1.61
Low: $0.65
High: $2.17

Volume

1,234,056 shs

Average Volume

1,177,624 shs

Market Capitalization

$473.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Who are the company insiders with the largest holdings of Precigen?

Precigen's top insider investors include:
  1. Randal J Kirk (Director)
  2. Helen Sabzevari (CEO)
  3. Steven Frank (Director)
  4. Jeffrey Thomas Perez (SVP)
  5. Donald P Lehr (Insider)
  6. Dean J Mitchell (Director)
  7. Harry Jr Thomasian (CFO)
  8. Rutul R Shah (COO)
Learn More about top insider investors at Precigen.

Who are the major institutional investors of Precigen?

Precigen's top institutional investors include:
  1. Patient Capital Management LLC — 6.11%
  2. Iridian Asset Management LLC CT — 1.79%
  3. Geode Capital Management LLC — 1.13%
  4. Charles Schwab Investment Management Inc. — 0.44%
  5. Northern Trust Corp — 0.40%
  6. Renaissance Technologies LLC — 0.36%
Learn More about top institutional investors of Precigen stock.

Which major investors are selling Precigen stock?

During the last quarter, PGEN stock was sold by these institutional investors:
  1. D. E. Shaw & Co. Inc.
  2. Renaissance Technologies LLC
  3. Summit Trail Advisors LLC
  4. Patient Capital Management LLC
  5. Synovus Financial Corp
  6. Price T Rowe Associates Inc. MD
  7. JPMorgan Chase & Co.
  8. Franklin Resources Inc.

Which major investors are buying Precigen stock?

Within the previous quarter, PGEN stock was bought by institutional investors including:
  1. Iridian Asset Management LLC CT
  2. LexAurum Advisors LLC
  3. Northern Trust Corp
  4. Cary Street Partners Financial LLC
  5. Fore Capital LLC
  6. XTX Topco Ltd
  7. CIBC Private Wealth Group LLC
  8. Stifel Financial Corp
Within the previous year, these company insiders have bought Precigen stock:
  1. Randal J Kirk (Director)
  2. Helen Sabzevari (CEO)
  3. Steven Frank (Director)
  4. Jeffrey Thomas Perez (SVP)
Learn More investors buying Precigen stock.